健康无应答者三种乙肝疫苗再接种方案的血清学应答:多中心开放随机对照优效试验
该多中心开放随机优效试验纳入480名健康乙肝疫苗无应答成人,比较四种再接种方案。3个月时Fendrix组和HBVaxPro-40组应答率显著高于对照组,Twinrix组未达显著。结论建议扩大Fendrix和HBVaxPro-40适应证用于无应答者再接种。
要点
- 健康成人乙肝疫苗无应答者可考虑Fendrix或HBVaxPro-40再接种。
- Fendrix组3个月应答率87%,HBVaxPro-40组83%,均显著优于对照。
- Twinrix组应答率80%,与对照组差异未达统计学显著。
核心结论
- Fendrix或HBVaxPro-40再接种健康无应答者,应答者比例显著高于重复初始疫苗,建议扩大这两种疫苗适应证。
研究设计与样本
- 多中心、平行组、随机、对照、优效试验,纳入16家荷兰中心18-80岁健康成人480例,随机分四组。
主要发现
- Fendrix组发生1例严重不良事件(眼部带状疱疹),判定与疫苗无关。
临床怎么用
- 对初始乙肝疫苗系列无应答(anti-HBs<10 IU/L)的健康成人,再接种可优先选择Fendrix或HBVaxPro-40。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serological non-response can be present after hepatitis B vaccination in healthy adults. We aimed to establish which of three revaccination regimens is most effective at inducing protective immunity METHODS: Healthy adults (aged 18-80 years) from 16 Dutch centres (13 public health services, two university hospitals, and one travel clinic) were included in this multicentre, parallel group, randomised, controlled, superiority trial. The inclusion criterion was vaccine non-response (hepatitis B surface antibody [anti-HBs] titre <10 IU/L) after a primary series with three doses of one type of recombinant vaccine against hepatitis B virus (either HBVaxPro-10 or Engerix-B at months 0, 1, and 6). Participants were individually randomly assigned (1:1:1:1) to a vaccination series of repeated initial vaccination (HBVaxPro 10 μg or Engerix-B 20 μg) as the control, or to Twinrix 20 μg, Fendrix 20 μg, or HBVaxPro 40 μg. We used a web-based randomisation programme, stratified by centre, with a block size of four. Participants and centres were unmasked to assignment after randomisation. Laboratory staff and investigators were masked to vaccine-group assignment. All revaccination schedules were identical, with intramuscular vaccinations at 0, 1, and 2 months. Anti-HBs was measured at 0, 1, 2, and 3 months. The primary outcome was the percentage of responders (anti-HBs titres ≥10 IU/L) at 3 months. Immunogenicity and safety analyses were based on an intention-to-vaccinate analysis, the immunogenicity analysis with last observation carried forward for missing data, and the Bonferroni and the Benjamini-Hochberg method were applied to correct for multiple testing. The trial was registered in the Dutch National Trial Register and inclusion has been stopped (identifier NL3011; EudraCT-number 2011-005627-40). FINDINGS: The participants were recruited between Nov 1, 2012, and Sept 1, 2017. 480 participants were randomly assigned and included in intention-to-vaccinate analyses: 124 (26%) to control, 118 (25%) to Twinrix, 114 (24%) to HBVaxPro-40, and 124 (26%) to Fendrix. At month 3 the percentage of responders was 83 (67%) of 124 (95% CI 57·9-75·1 in the control group, 94 (80%) of the 118 (71·3-86·5) in the Twinrix group, 95 (83%) of 114 (75·2-89·7) in the HBVaxPro-40 group, and 108 (87%) of 124 (79·9-92·4) in the Fendrix group. Compared with the control group, the percentage of responders was superior for the HBVaxPro-40 group (adjusted difference 21·6% [95% CI 10·4-32·7], p=0·0204 [Bonferroni corrected p value]) and the Fendrix group (26·3% [15·4-37·3], p=0·0006), but not the Twinrix group (25·0% [13·0-37·0]; p=0·0846). One serious adverse event occurred (herpes zoster ophthalmicus) in the Fendrix group, which was not attributed to the vaccine. INTERPRETATION: Revaccinating healthy non-responders with Fendrix or HBVaxPro-40 resulted in significantly higher proportions of responders and therefore indication for these vaccines should be expanded to enable revaccination of non-responders. FUNDING: National Institute for Public Health and the Environment.
引用
- Raven SFH, Hoebe CJPA, Vossen ACTM, et al. Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2019. PMID: 31629649. doi:10.1016/S1473-3099(19)30417-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。